Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven MF/SS, stage IB-IVB, and failed one standard systemic therapy. Skin biopsy must be within 3 months of beginning study medication~* At least the following wash-out from prior treatments:~  * ≥ 3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-cancer investigational agents (including monoclonal antibody)~ * \> 3 weeks for retinoids, interferons, vorinostat, romidepsin, denileukin diftitox and phototherapy~ * \> 2 wks for topical therapy (including topical steroid, retinoid, nitrogen mustard, or imiquimod)~* At least 18 years of age~* ECOG performance status of ≤ 2~* Must be able to commit to study schedule~* Absolute neutrophil count (ANC) ≥ 1000/uL~* Platelets ≥ 50,000/uL~* Bilirubin ≤ 2X upper limit of normal (ULN) (EXCEPTION: Gilbert's disease ≤ 3X ULN)~* Serum creatinine ≤ 2X ULN~* Alanine aminotransferase (ALT) ≤ 3X ULN~* Aspartate aminotransferase (AST) ≤ 3X ULN~* Negative serum beta-HCG pregnancy test result within 7 days of first treatment, if a woman of childbearing potential~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Mycosis fungoides (MF) with limited disease (stage IA) or central nervous system (CNS) disease~* Systemic or topical concomitant corticosteroid use for treatment of skin disease (EXCEPTION: Oral prednisone allowed at ≤ 10 mg/day)~* Known Grade 3 or higher (per NCI CTCAE v4.0 criteria) active systemic or cutaneous viral, bacterial, or fungal infection~* Known to be Hepatitis B or Hepatitis C antibody positive~* HIV-positive with have a measurable viral load while on antiretroviral medication~* Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.~* History of other malignancies during the past 3 years (EXCEPTIONS: non-melanoma skin cancer; curatively treated localized prostate cancer; curatively treated localized breast cancer; resected thyroid cancer; cervical intraepithelial neoplasia; or cervical carcinoma in situ on biopsy).~* Pregnant~* Breastfeeding~* Congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria.~* Any serious underlying medical condition that would impair subject's ability to receive or tolerate the planned treatment.~* Dementia or altered mental status that would preclude subject's understanding and rendering of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).